Precision Peptide Company Inc

As of April 30, 2026, Precision Peptide Company Inc has 45.71M shares outstanding.

As of April 30, 2026, Precision Peptide Company Inc maintains a current ratio of 3.37, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended April 30, 2026. Return on assets (ROA) is negative at -631.45, reflecting losses generated across the asset base. Inventory turnover of 2.05 indicates how many times Precision Peptide Company Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended April 30, 2026, Precision Peptide Company Inc generated 64,730.57 in revenue and converted that into -3.53M in net income, yielding earnings per share of -0.11. EBITDA reached -3.46M, while operating income came in at -2.07M.

These figures are as of April 30, 2026. Total book value stands at 659,011.88, with working capital of 659,011.88 providing operational flexibility.

Precision Peptide Company Inc produced -2.23M in operating cash flow over the twelve months ended April 30, 2026.

Over the twelve months ended April 30, 2026, Precision Peptide Company Inc posted a gross margin of 51.53, reflecting its pricing power and cost economics. The operating margin of -3,204.56 and net profit margin of -5,452.85 provide insight into operational efficiency.

Precision Peptide Company Inc's most recent stock split took place on February 18, 2025 with a 6:1 split ratio.